Brief: Parabilis Medicines - Estimated IPO Price Per Share Between $17 And $19 - SEC Filing
BRIEF-Parabilis Medicines - Estimated IPO Price Per Share Between $17 And $19 - SEC Filing June 4 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O:
PARABILIS MEDICINES - ESTIMATED IPO PRICE PER SHARE BETWEEN $17 AND $19 - SEC FILING
PARABILIS MEDICINES - ANNOUNCES IPO OF 25 MILLION SHARES - SEC FILING
PARABILIS MEDICINES INC SAYS REGENERON PHARMACEUTICALS AGREED TO BUY ABOUT $75 MILLION OF CO'S COMMON STOCK IN CONCURRENT PRIVATE PLACEMENT
PARABILIS MEDICINES - INTENDS TO USE ABOUT $150 MILLION OF IPO PROCEEDS TO CONTINUE ONGOING CLINICAL DEVELOPMENT OF ZOLUCATETIDE IN DESMOID TUMORS
PARABILIS MEDICINES-TO USE ABOUT $120 MILLION OF PROCEEDS TO CONTINUE ONGOING CLINICAL DEVELOPMENT OF ZOLUCATETIDE ACROSS SEVERAL ADDITIONAL INDICATIONS
PARABILIS MEDICINES-TO USE ABOUT $130 MILLION OF IPO PROCEEDS TO ADVANCE PIPELINE OF ADDITIONAL PROGRAMS
Source text: [ID:n0001193125-26-256398]
Further company coverage: REGN.O
((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Regeneron Pharmaceuticals
See all newsEyePoint to halve workforce after experimental drug fails second late-stage trial (updated)
EyePoint to cut workforce by half after experimental drug fails second late-stage trial
Brief: Sanofi, pCPA Sign Letter Of Intent For Dupixent® Across Four Indications In Dermatology, Respiratory Care
Brief: Regeneron Pharmaceuticals Says Pasatru Shows Sustained Efficacy & Consistent Safety Profile From Weeks 56 To 84
Brief: Regeneron Pharmaceuticals - Sanofi Enter Sixth Amendment To License And Collaboration Agreement